小宝8816的个人主页 - 老虎社区

小宝8816

小宝8816

暂无个人介绍

IP属地：未知

12关注

3粉丝

6主题

0勋章

2021-11-03

$Inovio Pharmaceuticals Inc(INO)$https://www.who.int/news/item/26-10-2021-who-statement-on-solidarity-trial-vaccines世界卫生组织所承认的，其中一种疫苗。

2021-11-03

时间证明一切。世界卫生组织所承认的其中一款疫苗。https://www.who.int/news/item/26-10-2021-who-statement-on-solidarity-trial-vaccines

Inovio制药(INO)扩大了新冠候选疫苗INO-4800的3期试验

2021-10-26

恭祝老虎！Go to the Moon 🌝

老虎证券收购香港持牌券商获香港证监会批准

2021-10-21

$Inovio Pharmaceuticals Inc(INO)$China approves first mixed-vaccine trial as Delta spreads.https://senegalbgc.org/blog/2021/10/20/china-approves-first-mixed-vaccine-trial-as-delta-spreads/

2021-10-14

Like please 👍🏻

4 Growth Stocks With 187% to 434% Upside, According to Wall Street

2021-10-11

第三期DNA疫苗。哥伦比亚。接下来会有更多国家参与!

抱歉，原内容已删除

2021-10-07

$Inovio Pharmaceuticals Inc(INO)$第三世界国家。的的确确需要这种不用冷藏的疫苗。https://youtu.be/Ht-Xk7G8-tQ

2021-08-31

$老虎证券(TIGR)$老虎来了🐯🐯🐯

2021-06-15

$ARK Space Exploration & Innovation ETF(ARKX)$等

2021-06-04

$Sundial Growers Inc.(SNDL)$赚不多！逢低再进。

2021-06-03

$1847 Goedeker(GOED)$看好这股可以到$4。

2021-06-02

$1847 Goedeker(GOED)$冲✈️✈️✈️

2021-05-24

$Inovio Pharmaceuticals Inc(INO)$站在高岗上。😪😪

2021-05-13

$老虎证券(TIGR)$冲呀！

2021-03-20

$Vaxart, Inc(VXRT)$站在高岗上。[笑哭]

2021-02-02

冲✈️✈️✈️

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3568282478603632","uuid":"3568282478603632","gmtCreate":1605188455598,"gmtModify":1612276444268,"name":"小宝8816","pinyin":"xb8816xiaobao8816","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":12,"tweetSize":16,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":6,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.76%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.51%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":841745328,"gmtCreate":1635945931070,"gmtModify":1635946865016,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>https://www.who.int/news/item/26-10-2021-who-statement-on-solidarity-trial-vaccines世界卫生组织所承认的，其中一种疫苗。","listText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>https://www.who.int/news/item/26-10-2021-who-statement-on-solidarity-trial-vaccines世界卫生组织所承认的，其中一种疫苗。","text":"$Inovio Pharmaceuticals Inc(INO)$https://www.who.int/news/item/26-10-2021-who-statement-on-solidarity-trial-vaccines世界卫生组织所承认的，其中一种疫苗。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841745328","isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841746348,"gmtCreate":1635945858637,"gmtModify":1635946855287,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"时间证明一切。世界卫生组织所承认的其中一款疫苗。https://www.who.int/news/item/26-10-2021-who-statement-on-solidarity-trial-vaccines","listText":"时间证明一切。世界卫生组织所承认的其中一款疫苗。https://www.who.int/news/item/26-10-2021-who-statement-on-solidarity-trial-vaccines","text":"时间证明一切。世界卫生组织所承认的其中一款疫苗。https://www.who.int/news/item/26-10-2021-who-statement-on-solidarity-trial-vaccines","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841746348","repostId":"2180628751","repostType":2,"repost":{"id":"2180628751","kind":"highlight","weMediaInfo":{"introduction":"凤凰网港股","home_visible":1,"media_name":"凤凰网港股","id":"1039806269","head_image":"https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817"},"pubTimestamp":1635941292,"share":"https://www.laohu8.com/m/news/2180628751?lang=&edition=full","pubTime":"2021-11-03 20:08","market":"us","language":"zh","title":"Inovio制药(INO)扩大了新冠候选疫苗INO-4800的3期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2180628751","media":"凤凰网港股","summary":"凤凰网港股|在获得印度监管部门的授权后，Inovio制药(INO)进一步扩大了新冠候选疫苗INO-4800的3期试验。","content":"<html><body><p>凤凰网港股|在获得印度监管部门的授权后，Inovio制药(INO)进一步扩大了新冠候选疫苗INO-4800的3期试验。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inovio制药(INO)扩大了新冠候选疫苗INO-4800的3期试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInovio制药(INO)扩大了新冠候选疫苗INO-4800的3期试验\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039806269\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">凤凰网港股 </p>\n<p class=\"h-time\">2021-11-03 20:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>凤凰网港股|在获得印度监管部门的授权后，Inovio制药(INO)进一步扩大了新冠候选疫苗INO-4800的3期试验。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/e559c5a8390713a5a8d4b07a2667368d","relate_stocks":{"INO":"伊诺维奥制药","01477":"欧康维视生物-B"},"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=b4d527291a2346626cbd3eda9f5230e2","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2180628751","content_text":"凤凰网港股|在获得印度监管部门的授权后，Inovio制药(INO)进一步扩大了新冠候选疫苗INO-4800的3期试验。","news_type":1},"isVote":1,"tweetType":1,"viewCount":774,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":852923566,"gmtCreate":1635235898840,"gmtModify":1635236233437,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"恭祝老虎！Go to the Moon 🌝&nbsp;","listText":"恭祝老虎！Go to the Moon 🌝&nbsp;","text":"恭祝老虎！Go to the Moon 🌝","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/852923566","repostId":"1114369979","repostType":2,"repost":{"id":"1114369979","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635235237,"share":"https://www.laohu8.com/m/news/1114369979?lang=&edition=full","pubTime":"2021-10-26 16:00","market":"us","language":"zh","title":"老虎证券收购香港持牌券商获香港证监会批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1114369979","media":"老虎资讯综合","summary":"美东时间10月26日盘前，老虎证券（NASDAQ：TIGR）发布公告：公司收购一家香港券商（海悦证券，中央编号：BMU940）已获香港证监会（SFC）批准。该券商持有香港第1、2类牌照，此次收购正式完","content":"<p>美东时间10月26日盘前，老虎证券（NASDAQ：TIGR）发布公告：公司收购一家香港券商（海悦证券，中央编号：BMU940）已获香港证监会（SFC）批准。该券商持有香港第1、2类牌照，此次收购正式完成后，老虎证券可进入香港市场为当地客户提供证券经纪、期货经纪等服务。</p>\n<p>老虎证券创始人及CEO巫天华表示：“香港一直是全球最活跃的金融市场之一，我们非常期待能进入香港金融市场，结合我们过去七年积累的产品技术、服务经验，为香港当地投资者提供更便捷和优质的全球投资体验，为香港市场高速发展贡献一份力量。”</p>\n<p>此前，老虎证券已在美国、新加坡、澳大利亚、新西兰拥有33张金融类牌照和资质。基于牌照和优秀的产品服务体验，2020年，公司以新加坡为首站开启国际化战略。截至2021年二季度末，老虎证券全球开户客户数为164.9万，季度内超六成新增入金客户来自海外。此次收购香港证券牌照则代表老虎证券又一个重要里程碑，公司服务区域将得到进一步扩展，为长期发展奠定了更坚实的基础。</p>\n<p>老虎证券成立于2014年，是一家高速成长的全球科技券商，聚焦技术自研，公司旨在通过金融科技提高投资效率，使每个人轻松连接全球资本市场。目前，老虎证券以经纪业务为核心，向全球投资者提供一个账户交易全球主要市场金融产品的一站式投资服务。此外，公司还提供投行、ESOP（股权激励计划）等机构服务以及财富管理、投资者教育等多种增值服务。今年，老虎证券获纳入MSCI中国全股票指数（MSCI China All Shares Index），国际关注度进一步提高。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>老虎证券收购香港持牌券商获香港证监会批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n老虎证券收购香港持牌券商获香港证监会批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-10-26 16:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>美东时间10月26日盘前，老虎证券（NASDAQ：TIGR）发布公告：公司收购一家香港券商（海悦证券，中央编号：BMU940）已获香港证监会（SFC）批准。该券商持有香港第1、2类牌照，此次收购正式完成后，老虎证券可进入香港市场为当地客户提供证券经纪、期货经纪等服务。</p>\n<p>老虎证券创始人及CEO巫天华表示：“香港一直是全球最活跃的金融市场之一，我们非常期待能进入香港金融市场，结合我们过去七年积累的产品技术、服务经验，为香港当地投资者提供更便捷和优质的全球投资体验，为香港市场高速发展贡献一份力量。”</p>\n<p>此前，老虎证券已在美国、新加坡、澳大利亚、新西兰拥有33张金融类牌照和资质。基于牌照和优秀的产品服务体验，2020年，公司以新加坡为首站开启国际化战略。截至2021年二季度末，老虎证券全球开户客户数为164.9万，季度内超六成新增入金客户来自海外。此次收购香港证券牌照则代表老虎证券又一个重要里程碑，公司服务区域将得到进一步扩展，为长期发展奠定了更坚实的基础。</p>\n<p>老虎证券成立于2014年，是一家高速成长的全球科技券商，聚焦技术自研，公司旨在通过金融科技提高投资效率，使每个人轻松连接全球资本市场。目前，老虎证券以经纪业务为核心，向全球投资者提供一个账户交易全球主要市场金融产品的一站式投资服务。此外，公司还提供投行、ESOP（股权激励计划）等机构服务以及财富管理、投资者教育等多种增值服务。今年，老虎证券获纳入MSCI中国全股票指数（MSCI China All Shares Index），国际关注度进一步提高。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/2b649bd69bfc05cb75eea3d2165257a2","relate_stocks":{"TIGR":"老虎证券"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114369979","content_text":"美东时间10月26日盘前，老虎证券（NASDAQ：TIGR）发布公告：公司收购一家香港券商（海悦证券，中央编号：BMU940）已获香港证监会（SFC）批准。该券商持有香港第1、2类牌照，此次收购正式完成后，老虎证券可进入香港市场为当地客户提供证券经纪、期货经纪等服务。\n老虎证券创始人及CEO巫天华表示：“香港一直是全球最活跃的金融市场之一，我们非常期待能进入香港金融市场，结合我们过去七年积累的产品技术、服务经验，为香港当地投资者提供更便捷和优质的全球投资体验，为香港市场高速发展贡献一份力量。”\n此前，老虎证券已在美国、新加坡、澳大利亚、新西兰拥有33张金融类牌照和资质。基于牌照和优秀的产品服务体验，2020年，公司以新加坡为首站开启国际化战略。截至2021年二季度末，老虎证券全球开户客户数为164.9万，季度内超六成新增入金客户来自海外。此次收购香港证券牌照则代表老虎证券又一个重要里程碑，公司服务区域将得到进一步扩展，为长期发展奠定了更坚实的基础。\n老虎证券成立于2014年，是一家高速成长的全球科技券商，聚焦技术自研，公司旨在通过金融科技提高投资效率，使每个人轻松连接全球资本市场。目前，老虎证券以经纪业务为核心，向全球投资者提供一个账户交易全球主要市场金融产品的一站式投资服务。此外，公司还提供投行、ESOP（股权激励计划）等机构服务以及财富管理、投资者教育等多种增值服务。今年，老虎证券获纳入MSCI中国全股票指数（MSCI China All Shares Index），国际关注度进一步提高。","news_type":1},"isVote":1,"tweetType":1,"viewCount":659,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853897092,"gmtCreate":1634786157505,"gmtModify":1634788165282,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>China approves first mixed-vaccine trial as Delta spreads.https://senegalbgc.org/blog/2021/10/20/china-approves-first-mixed-vaccine-trial-as-delta-spreads/","listText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>China approves first mixed-vaccine trial as Delta spreads.https://senegalbgc.org/blog/2021/10/20/china-approves-first-mixed-vaccine-trial-as-delta-spreads/","text":"$Inovio Pharmaceuticals Inc(INO)$China approves first mixed-vaccine trial as Delta spreads.https://senegalbgc.org/blog/2021/10/20/china-approves-first-mixed-vaccine-trial-as-delta-spreads/","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853897092","isVote":1,"tweetType":1,"viewCount":782,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825889408,"gmtCreate":1634217036604,"gmtModify":1634217036658,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"Like please 👍🏻&nbsp;","listText":"Like please 👍🏻&nbsp;","text":"Like please 👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825889408","repostId":"2175518141","repostType":2,"repost":{"id":"2175518141","kind":"highlight","pubTimestamp":1634181120,"share":"https://www.laohu8.com/m/news/2175518141?lang=&edition=full","pubTime":"2021-10-14 11:12","market":"us","language":"en","title":"4 Growth Stocks With 187% to 434% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2175518141","media":"Motley Fool","summary":"Based on analysts' loftiest price targets, these companies could nearly triple or potentially quintuple investors' money over the next year.","content":"<p>For much of the past 18 months, Wall Street and investors have enjoyed an historic stock market rally. Since bottoming out on March 23, 2020, the widely followed <b>S&amp;P 500</b> has doubled in value. For some context, the S&amp;P 500 has average an annualized total return (including dividends paid) of closer to 11% since the beginning of 1980.</p>\n<p>But for some stocks, there's plenty of upside still to come. According to high-water price targets from select analysts and/or Wall Street investment banks, the following four growth stocks offer share-price upside ranging from a low of 187% to a high of 434% over the coming 12 months.</p>\n<h2>Plug Power: Implied upside of 187%</h2>\n<p>The first high-growth stock with the potential to get investors' motors running is hydrogen fuel-cell solutions provider <b>Plug Power</b> (NASDAQ:PLUG). Analyst Amit Dayal of H.C. Wainwright sees Plug Power heading to $78, which is a far cry from its closing price of $27.19, as of this past weekend. Dayal's Street-high price target implies a 187% increase in Plug's shares.</p>\n<p>The excitement surrounding Plug Power has to do with developed countries emphasizing green-energy alternatives to reduce carbon emissions. Plug's hydrogen fuel cells can be used to power consumer and commercial vehicles, and they have industrial applications, as well (e.g., forklifts). Further, there's an opportunity for the company to benefit at multiple levels of this green-energy shift, such as in building hydrogen refilling stations.</p>\n<p>The buzz surrounding this company hit a crescendo in January, shortly after Plug landed two major partnerships. First, SK Group took a 10% equity stake in the company and agreed to form a joint venture to bring fuel-cell technology to South Korea and other Asian countries. A few days later, Plug and French automaker <b>Renault</b> struck an agreement to form a joint venture to go after Europe's light commercial-vehicle market.</p>\n<p>There's absolutely no question that Plug Power has top-notch joint-venture partners and an incredible opportunity at its doorstep. The big question is: Can it grow into its current $16 billion market cap with profitability still years away? To that end, I'm not so certain.</p>\n<h2>Columbia Care: Implied upside of 228%</h2>\n<p>Marijuana stocks are another source of supercharged growth potential. In particular, U.S. multistate operator (MSO) <b>Columbia Care</b> (OTC:CCHWF) offers jaw-dropping upside. With the highest price target on Wall Street calling for $12 a share, and Columbia Care ending the previous week at $3.66, the upside potential here totals 228% over the coming year.</p>\n<p>Like a number of smartly run MSOs, Columbia Care has predominantly targeted limited-license cannabis markets. These are markets where regulators purposely limit how many dispensaries can open, as well as how many licenses a single business can hold. By planting its flag in limited-license markets like Ohio, Virginia, and Pennsylvania, Columbia Care is ensuring that it'll have a fair shot to build up its brands and garner a loyal following in potential billion-dollar markets without being overrun by other MSOs that have deeper pockets.</p>\n<p>The other factor that really stands out with Columbia Care is its penchant for inorganic growth. This is a company that's been pulling the trigger on multiple acquisitions each year to expand its reach. As of last week, it had 75 operating dispensaries in legalized states.</p>\n<p>For the moment, the <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time costs associated with acquisitions appears to be holding down Columbia Care's bottom line, as well as its valuation. But if the company's management team can effectively build up its brand in a number of key markets, this lofty price target may not be out of reach.</p>\n<h2>Exelixis: Implied upside of 201%</h2>\n<p>Biotech stocks can be like the roulette wheel of Wall Street. While the odds of a company developing a breakthrough drug aren't great, the payoff, if successful, can be huge.</p>\n<p>In the case of <b>Exelixis</b> (NASDAQ:EXEL), the payoff has been substantial. But according to analyst Michael King of H.C. Wainwright, this company has the potential to hit $65 a share. This would effectively triple its valuation, based on where it closed this past week.</p>\n<p>The key to Exelixis' long-term success rests with cancer drug Cabometyx, which is approved to treat first- and second-line renal cell carcinoma and advanced hepatocellular carcinoma. By no later than next year, it should be generating north of $1 billion in recurring annual sales.</p>\n<p>What's so intriguing about Exelixis' lead drug is that it's being studied in approximately six dozen clinical trials as a combination treatment or monotherapy. Though not all of these studies will be successful, it nevertheless offers a solid opportunity for Cabometyx's label to expand over time.</p>\n<p>Exelixis is also sitting on a mountain of cash and investments -- it's expected to end the year with between $1.7 billion and $1.8 billion. This capital is helping to fuel its internal research engine and could be used to acquire other therapies or businesses. While I don't believe Exelixis will come close to $65 a share in the near term, I do foresee healthy upside in its future.</p>\n<h2>Inovio Pharmaceuticals: Implied upside of 434%</h2>\n<p>But the crème de la crème of upside opportunity, at least on this list, is clinical-stage biotech stock <b>Inovio Pharmaceuticals</b> (NASDAQ:INO). According to analyst Hartaj Singh of Oppenheimer, Inovio is forecast to hit $35 a share. Based on its $6.55 closing price last week, this implies up to 434% upside in Inovio's shares.</p>\n<p>Most of Singh's bullishness is centered around Inovio's development of a coronavirus disease 2019 (COVID-19) vaccine. With billions of people worldwide still needing to be inoculated, there's room for additional vaccine players.</p>\n<p>On the other hand, Inovio's development of its COVID-19 vaccine, INO-4800, has been just as dubious as its long-term drug-development track record. Last year, it looked as if Inovio had a real shot to be one of the first developers to hit the market with a COVID-19 vaccine. Unfortunately, Inovio's plans were derailed by partial clinical holds in the United States. To boot, the U.S. eventually pulled phase 3 trial funding, which has forced Inovio to conduct its large-scale phase 3 study in Mexico and other countries around the globe.</p>\n<p>Perhaps the bigger worry here is that, despite a robust clinical pipeline, Inovio has yet to bring a drug to pharmacy shelves more than 40 years after its founding. Inovio has been lucky enough to raise capital to keep its research going, but it's never been able to deliver on the hype surrounding the company. Suffice it to say, I don't foresee a $35 price target coming to fruition anytime soon, if ever.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Growth Stocks With 187% to 434% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Growth Stocks With 187% to 434% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-14 11:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/13/4-growth-stocks-with-187-to-434-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For much of the past 18 months, Wall Street and investors have enjoyed an historic stock market rally. Since bottoming out on March 23, 2020, the widely followed S&P 500 has doubled in value. For some...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/13/4-growth-stocks-with-187-to-434-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLUG":"普拉格能源","EXEL":"伊克力西斯","INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/10/13/4-growth-stocks-with-187-to-434-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175518141","content_text":"For much of the past 18 months, Wall Street and investors have enjoyed an historic stock market rally. Since bottoming out on March 23, 2020, the widely followed S&P 500 has doubled in value. For some context, the S&P 500 has average an annualized total return (including dividends paid) of closer to 11% since the beginning of 1980.\nBut for some stocks, there's plenty of upside still to come. According to high-water price targets from select analysts and/or Wall Street investment banks, the following four growth stocks offer share-price upside ranging from a low of 187% to a high of 434% over the coming 12 months.\nPlug Power: Implied upside of 187%\nThe first high-growth stock with the potential to get investors' motors running is hydrogen fuel-cell solutions provider Plug Power (NASDAQ:PLUG). Analyst Amit Dayal of H.C. Wainwright sees Plug Power heading to $78, which is a far cry from its closing price of $27.19, as of this past weekend. Dayal's Street-high price target implies a 187% increase in Plug's shares.\nThe excitement surrounding Plug Power has to do with developed countries emphasizing green-energy alternatives to reduce carbon emissions. Plug's hydrogen fuel cells can be used to power consumer and commercial vehicles, and they have industrial applications, as well (e.g., forklifts). Further, there's an opportunity for the company to benefit at multiple levels of this green-energy shift, such as in building hydrogen refilling stations.\nThe buzz surrounding this company hit a crescendo in January, shortly after Plug landed two major partnerships. First, SK Group took a 10% equity stake in the company and agreed to form a joint venture to bring fuel-cell technology to South Korea and other Asian countries. A few days later, Plug and French automaker Renault struck an agreement to form a joint venture to go after Europe's light commercial-vehicle market.\nThere's absolutely no question that Plug Power has top-notch joint-venture partners and an incredible opportunity at its doorstep. The big question is: Can it grow into its current $16 billion market cap with profitability still years away? To that end, I'm not so certain.\nColumbia Care: Implied upside of 228%\nMarijuana stocks are another source of supercharged growth potential. In particular, U.S. multistate operator (MSO) Columbia Care (OTC:CCHWF) offers jaw-dropping upside. With the highest price target on Wall Street calling for $12 a share, and Columbia Care ending the previous week at $3.66, the upside potential here totals 228% over the coming year.\nLike a number of smartly run MSOs, Columbia Care has predominantly targeted limited-license cannabis markets. These are markets where regulators purposely limit how many dispensaries can open, as well as how many licenses a single business can hold. By planting its flag in limited-license markets like Ohio, Virginia, and Pennsylvania, Columbia Care is ensuring that it'll have a fair shot to build up its brands and garner a loyal following in potential billion-dollar markets without being overrun by other MSOs that have deeper pockets.\nThe other factor that really stands out with Columbia Care is its penchant for inorganic growth. This is a company that's been pulling the trigger on multiple acquisitions each year to expand its reach. As of last week, it had 75 operating dispensaries in legalized states.\nFor the moment, the one-time costs associated with acquisitions appears to be holding down Columbia Care's bottom line, as well as its valuation. But if the company's management team can effectively build up its brand in a number of key markets, this lofty price target may not be out of reach.\nExelixis: Implied upside of 201%\nBiotech stocks can be like the roulette wheel of Wall Street. While the odds of a company developing a breakthrough drug aren't great, the payoff, if successful, can be huge.\nIn the case of Exelixis (NASDAQ:EXEL), the payoff has been substantial. But according to analyst Michael King of H.C. Wainwright, this company has the potential to hit $65 a share. This would effectively triple its valuation, based on where it closed this past week.\nThe key to Exelixis' long-term success rests with cancer drug Cabometyx, which is approved to treat first- and second-line renal cell carcinoma and advanced hepatocellular carcinoma. By no later than next year, it should be generating north of $1 billion in recurring annual sales.\nWhat's so intriguing about Exelixis' lead drug is that it's being studied in approximately six dozen clinical trials as a combination treatment or monotherapy. Though not all of these studies will be successful, it nevertheless offers a solid opportunity for Cabometyx's label to expand over time.\nExelixis is also sitting on a mountain of cash and investments -- it's expected to end the year with between $1.7 billion and $1.8 billion. This capital is helping to fuel its internal research engine and could be used to acquire other therapies or businesses. While I don't believe Exelixis will come close to $65 a share in the near term, I do foresee healthy upside in its future.\nInovio Pharmaceuticals: Implied upside of 434%\nBut the crème de la crème of upside opportunity, at least on this list, is clinical-stage biotech stock Inovio Pharmaceuticals (NASDAQ:INO). According to analyst Hartaj Singh of Oppenheimer, Inovio is forecast to hit $35 a share. Based on its $6.55 closing price last week, this implies up to 434% upside in Inovio's shares.\nMost of Singh's bullishness is centered around Inovio's development of a coronavirus disease 2019 (COVID-19) vaccine. With billions of people worldwide still needing to be inoculated, there's room for additional vaccine players.\nOn the other hand, Inovio's development of its COVID-19 vaccine, INO-4800, has been just as dubious as its long-term drug-development track record. Last year, it looked as if Inovio had a real shot to be one of the first developers to hit the market with a COVID-19 vaccine. Unfortunately, Inovio's plans were derailed by partial clinical holds in the United States. To boot, the U.S. eventually pulled phase 3 trial funding, which has forced Inovio to conduct its large-scale phase 3 study in Mexico and other countries around the globe.\nPerhaps the bigger worry here is that, despite a robust clinical pipeline, Inovio has yet to bring a drug to pharmacy shelves more than 40 years after its founding. Inovio has been lucky enough to raise capital to keep its research going, but it's never been able to deliver on the hype surrounding the company. Suffice it to say, I don't foresee a $35 price target coming to fruition anytime soon, if ever.","news_type":1},"isVote":1,"tweetType":1,"viewCount":686,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":826034606,"gmtCreate":1633957257586,"gmtModify":1633957257586,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"第三期DNA疫苗。哥伦比亚。接下来会有更多国家参与!","listText":"第三期DNA疫苗。哥伦比亚。接下来会有更多国家参与!","text":"第三期DNA疫苗。哥伦比亚。接下来会有更多国家参与!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/826034606","repostId":"2174902634","repostType":2,"isVote":1,"tweetType":1,"viewCount":797,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":823110933,"gmtCreate":1633597225074,"gmtModify":1633602165796,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>第三世界国家。的的确确需要这种不用冷藏的疫苗。https://youtu.be/Ht-Xk7G8-tQ","listText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>第三世界国家。的的确确需要这种不用冷藏的疫苗。https://youtu.be/Ht-Xk7G8-tQ","text":"$Inovio Pharmaceuticals Inc(INO)$第三世界国家。的的确确需要这种不用冷藏的疫苗。https://youtu.be/Ht-Xk7G8-tQ","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/823110933","isVote":1,"tweetType":1,"viewCount":701,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":818607698,"gmtCreate":1630400447114,"gmtModify":1631891021873,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>老虎来了🐯🐯🐯","listText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>老虎来了🐯🐯🐯","text":"$老虎证券(TIGR)$老虎来了🐯🐯🐯","images":[{"img":"https://static.tigerbbs.com/2b3db5dfa6d2f15308b0a95dba4d1967","width":"1242","height":"2001"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/818607698","isVote":1,"tweetType":1,"viewCount":616,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":187882488,"gmtCreate":1623749328344,"gmtModify":1631888457342,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ARKX\">$ARK Space Exploration &amp; Innovation ETF(ARKX)$</a>等","listText":"<a href=\"https://laohu8.com/S/ARKX\">$ARK Space Exploration &amp; Innovation ETF(ARKX)$</a>等","text":"$ARK Space Exploration & Innovation ETF(ARKX)$等","images":[{"img":"https://static.tigerbbs.com/3df57949fdc3d38569903e1b98fec77a","width":"1242","height":"1767"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/187882488","isVote":1,"tweetType":1,"viewCount":459,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":116013387,"gmtCreate":1622765481449,"gmtModify":1631891021886,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>赚不多！逢低再进。","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>赚不多！逢低再进。","text":"$Sundial Growers Inc.(SNDL)$赚不多！逢低再进。","images":[{"img":"https://static.tigerbbs.com/438ba6cb7488b7eed8d8e947db512e78","width":"1242","height":"1767"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/116013387","isVote":1,"tweetType":1,"viewCount":1173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":111667864,"gmtCreate":1622679420058,"gmtModify":1631887563799,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GOED\">$1847 Goedeker(GOED)$</a>看好这股可以到$4。","listText":"<a href=\"https://laohu8.com/S/GOED\">$1847 Goedeker(GOED)$</a>看好这股可以到$4。","text":"$1847 Goedeker(GOED)$看好这股可以到$4。","images":[{"img":"https://static.tigerbbs.com/d4fd28d104e843043651da648ead6b71","width":"1242","height":"1767"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/111667864","isVote":1,"tweetType":1,"viewCount":463,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":113979864,"gmtCreate":1622592423658,"gmtModify":1631887563855,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GOED\">$1847 Goedeker(GOED)$</a>冲✈️✈️✈️","listText":"<a href=\"https://laohu8.com/S/GOED\">$1847 Goedeker(GOED)$</a>冲✈️✈️✈️","text":"$1847 Goedeker(GOED)$冲✈️✈️✈️","images":[{"img":"https://static.tigerbbs.com/d056b2cedd6f5fb9404db4ebec21f328","width":"1242","height":"1767"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/113979864","isVote":1,"tweetType":1,"viewCount":456,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":131932807,"gmtCreate":1621820688409,"gmtModify":1631884955516,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>站在高岗上。😪😪","listText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>站在高岗上。😪😪","text":"$Inovio Pharmaceuticals Inc(INO)$站在高岗上。😪😪","images":[{"img":"https://static.tigerbbs.com/23cf89983a0662c59aec06c40afba7f9","width":"1242","height":"1767"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/131932807","isVote":1,"tweetType":1,"viewCount":783,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3561384114025000","authorId":"3561384114025000","name":"8股tesla","avatar":"https://static.tigerbbs.com/554de077487a8db8a1ac45fd0b5c9587","crmLevel":5,"crmLevelSwitch":0,"idStr":"3561384114025000","authorIdStr":"3561384114025000"},"content":"一起做股东","text":"一起做股东","html":"一起做股东"}],"imageCount":1,"langContent":"CN","totalScore":0},{"id":191231052,"gmtCreate":1620879564076,"gmtModify":1631891021903,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>冲呀！","listText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>冲呀！","text":"$老虎证券(TIGR)$冲呀！","images":[{"img":"https://static.tigerbbs.com/579ce2043bf63a8ece1268e154050a5d","width":"1242","height":"2001"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/191231052","isVote":1,"tweetType":1,"viewCount":531,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":350263089,"gmtCreate":1616213207841,"gmtModify":1631887437937,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>站在高岗上。[笑哭]&nbsp;","listText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>站在高岗上。[笑哭]&nbsp;","text":"$Vaxart, Inc(VXRT)$站在高岗上。[笑哭]","images":[{"img":"https://static.tigerbbs.com/dddf2c1f0cf91aafe4a74311cdc8dd41","width":"1242","height":"1767"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/350263089","isVote":1,"tweetType":1,"viewCount":375,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":315435988,"gmtCreate":1612270587644,"gmtModify":1703759605156,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"冲✈️✈️✈️","listText":"冲✈️✈️✈️","text":"冲✈️✈️✈️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/315435988","repostId":"1179718017","repostType":4,"isVote":1,"tweetType":1,"viewCount":209,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"idStr":"3527667803686145","authorIdStr":"3527667803686145"},"content":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引"}],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":131932807,"gmtCreate":1621820688409,"gmtModify":1631884955516,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>站在高岗上。😪😪","listText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>站在高岗上。😪😪","text":"$Inovio Pharmaceuticals Inc(INO)$站在高岗上。😪😪","images":[{"img":"https://static.tigerbbs.com/23cf89983a0662c59aec06c40afba7f9","width":"1242","height":"1767"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/131932807","isVote":1,"tweetType":1,"viewCount":783,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3561384114025000","authorId":"3561384114025000","name":"8股tesla","avatar":"https://static.tigerbbs.com/554de077487a8db8a1ac45fd0b5c9587","crmLevel":5,"crmLevelSwitch":0,"idStr":"3561384114025000","authorIdStr":"3561384114025000"},"content":"一起做股东","text":"一起做股东","html":"一起做股东"}],"imageCount":1,"langContent":"CN","totalScore":0},{"id":116013387,"gmtCreate":1622765481449,"gmtModify":1631891021886,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>赚不多！逢低再进。","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>赚不多！逢低再进。","text":"$Sundial Growers Inc.(SNDL)$赚不多！逢低再进。","images":[{"img":"https://static.tigerbbs.com/438ba6cb7488b7eed8d8e947db512e78","width":"1242","height":"1767"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/116013387","isVote":1,"tweetType":1,"viewCount":1173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":111667864,"gmtCreate":1622679420058,"gmtModify":1631887563799,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GOED\">$1847 Goedeker(GOED)$</a>看好这股可以到$4。","listText":"<a href=\"https://laohu8.com/S/GOED\">$1847 Goedeker(GOED)$</a>看好这股可以到$4。","text":"$1847 Goedeker(GOED)$看好这股可以到$4。","images":[{"img":"https://static.tigerbbs.com/d4fd28d104e843043651da648ead6b71","width":"1242","height":"1767"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/111667864","isVote":1,"tweetType":1,"viewCount":463,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":350263089,"gmtCreate":1616213207841,"gmtModify":1631887437937,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>站在高岗上。[笑哭]&nbsp;","listText":"<a href=\"https://laohu8.com/S/VXRT\">$Vaxart, Inc(VXRT)$</a>站在高岗上。[笑哭]&nbsp;","text":"$Vaxart, Inc(VXRT)$站在高岗上。[笑哭]","images":[{"img":"https://static.tigerbbs.com/dddf2c1f0cf91aafe4a74311cdc8dd41","width":"1242","height":"1767"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/350263089","isVote":1,"tweetType":1,"viewCount":375,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":191231052,"gmtCreate":1620879564076,"gmtModify":1631891021903,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>冲呀！","listText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>冲呀！","text":"$老虎证券(TIGR)$冲呀！","images":[{"img":"https://static.tigerbbs.com/579ce2043bf63a8ece1268e154050a5d","width":"1242","height":"2001"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/191231052","isVote":1,"tweetType":1,"viewCount":531,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":315435988,"gmtCreate":1612270587644,"gmtModify":1703759605156,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"冲✈️✈️✈️","listText":"冲✈️✈️✈️","text":"冲✈️✈️✈️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/315435988","repostId":"1179718017","repostType":4,"isVote":1,"tweetType":1,"viewCount":209,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"idStr":"3527667803686145","authorIdStr":"3527667803686145"},"content":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":187882488,"gmtCreate":1623749328344,"gmtModify":1631888457342,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ARKX\">$ARK Space Exploration &amp; Innovation ETF(ARKX)$</a>等","listText":"<a href=\"https://laohu8.com/S/ARKX\">$ARK Space Exploration &amp; Innovation ETF(ARKX)$</a>等","text":"$ARK Space Exploration & Innovation ETF(ARKX)$等","images":[{"img":"https://static.tigerbbs.com/3df57949fdc3d38569903e1b98fec77a","width":"1242","height":"1767"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/187882488","isVote":1,"tweetType":1,"viewCount":459,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":113979864,"gmtCreate":1622592423658,"gmtModify":1631887563855,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GOED\">$1847 Goedeker(GOED)$</a>冲✈️✈️✈️","listText":"<a href=\"https://laohu8.com/S/GOED\">$1847 Goedeker(GOED)$</a>冲✈️✈️✈️","text":"$1847 Goedeker(GOED)$冲✈️✈️✈️","images":[{"img":"https://static.tigerbbs.com/d056b2cedd6f5fb9404db4ebec21f328","width":"1242","height":"1767"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/113979864","isVote":1,"tweetType":1,"viewCount":456,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":853897092,"gmtCreate":1634786157505,"gmtModify":1634788165282,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>China approves first mixed-vaccine trial as Delta spreads.https://senegalbgc.org/blog/2021/10/20/china-approves-first-mixed-vaccine-trial-as-delta-spreads/","listText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>China approves first mixed-vaccine trial as Delta spreads.https://senegalbgc.org/blog/2021/10/20/china-approves-first-mixed-vaccine-trial-as-delta-spreads/","text":"$Inovio Pharmaceuticals Inc(INO)$China approves first mixed-vaccine trial as Delta spreads.https://senegalbgc.org/blog/2021/10/20/china-approves-first-mixed-vaccine-trial-as-delta-spreads/","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853897092","isVote":1,"tweetType":1,"viewCount":782,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841745328,"gmtCreate":1635945931070,"gmtModify":1635946865016,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>https://www.who.int/news/item/26-10-2021-who-statement-on-solidarity-trial-vaccines世界卫生组织所承认的，其中一种疫苗。","listText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>https://www.who.int/news/item/26-10-2021-who-statement-on-solidarity-trial-vaccines世界卫生组织所承认的，其中一种疫苗。","text":"$Inovio Pharmaceuticals Inc(INO)$https://www.who.int/news/item/26-10-2021-who-statement-on-solidarity-trial-vaccines世界卫生组织所承认的，其中一种疫苗。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841745328","isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":823110933,"gmtCreate":1633597225074,"gmtModify":1633602165796,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>第三世界国家。的的确确需要这种不用冷藏的疫苗。https://youtu.be/Ht-Xk7G8-tQ","listText":"<a href=\"https://laohu8.com/S/INO\">$Inovio Pharmaceuticals Inc(INO)$</a>第三世界国家。的的确确需要这种不用冷藏的疫苗。https://youtu.be/Ht-Xk7G8-tQ","text":"$Inovio Pharmaceuticals Inc(INO)$第三世界国家。的的确确需要这种不用冷藏的疫苗。https://youtu.be/Ht-Xk7G8-tQ","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/823110933","isVote":1,"tweetType":1,"viewCount":701,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":852923566,"gmtCreate":1635235898840,"gmtModify":1635236233437,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"恭祝老虎！Go to the Moon 🌝&nbsp;","listText":"恭祝老虎！Go to the Moon 🌝&nbsp;","text":"恭祝老虎！Go to the Moon 🌝","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/852923566","repostId":"1114369979","repostType":2,"repost":{"id":"1114369979","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635235237,"share":"https://www.laohu8.com/m/news/1114369979?lang=&edition=full","pubTime":"2021-10-26 16:00","market":"us","language":"zh","title":"老虎证券收购香港持牌券商获香港证监会批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1114369979","media":"老虎资讯综合","summary":"美东时间10月26日盘前，老虎证券（NASDAQ：TIGR）发布公告：公司收购一家香港券商（海悦证券，中央编号：BMU940）已获香港证监会（SFC）批准。该券商持有香港第1、2类牌照，此次收购正式完","content":"<p>美东时间10月26日盘前，老虎证券（NASDAQ：TIGR）发布公告：公司收购一家香港券商（海悦证券，中央编号：BMU940）已获香港证监会（SFC）批准。该券商持有香港第1、2类牌照，此次收购正式完成后，老虎证券可进入香港市场为当地客户提供证券经纪、期货经纪等服务。</p>\n<p>老虎证券创始人及CEO巫天华表示：“香港一直是全球最活跃的金融市场之一，我们非常期待能进入香港金融市场，结合我们过去七年积累的产品技术、服务经验，为香港当地投资者提供更便捷和优质的全球投资体验，为香港市场高速发展贡献一份力量。”</p>\n<p>此前，老虎证券已在美国、新加坡、澳大利亚、新西兰拥有33张金融类牌照和资质。基于牌照和优秀的产品服务体验，2020年，公司以新加坡为首站开启国际化战略。截至2021年二季度末，老虎证券全球开户客户数为164.9万，季度内超六成新增入金客户来自海外。此次收购香港证券牌照则代表老虎证券又一个重要里程碑，公司服务区域将得到进一步扩展，为长期发展奠定了更坚实的基础。</p>\n<p>老虎证券成立于2014年，是一家高速成长的全球科技券商，聚焦技术自研，公司旨在通过金融科技提高投资效率，使每个人轻松连接全球资本市场。目前，老虎证券以经纪业务为核心，向全球投资者提供一个账户交易全球主要市场金融产品的一站式投资服务。此外，公司还提供投行、ESOP（股权激励计划）等机构服务以及财富管理、投资者教育等多种增值服务。今年，老虎证券获纳入MSCI中国全股票指数（MSCI China All Shares Index），国际关注度进一步提高。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>老虎证券收购香港持牌券商获香港证监会批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n老虎证券收购香港持牌券商获香港证监会批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-10-26 16:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>美东时间10月26日盘前，老虎证券（NASDAQ：TIGR）发布公告：公司收购一家香港券商（海悦证券，中央编号：BMU940）已获香港证监会（SFC）批准。该券商持有香港第1、2类牌照，此次收购正式完成后，老虎证券可进入香港市场为当地客户提供证券经纪、期货经纪等服务。</p>\n<p>老虎证券创始人及CEO巫天华表示：“香港一直是全球最活跃的金融市场之一，我们非常期待能进入香港金融市场，结合我们过去七年积累的产品技术、服务经验，为香港当地投资者提供更便捷和优质的全球投资体验，为香港市场高速发展贡献一份力量。”</p>\n<p>此前，老虎证券已在美国、新加坡、澳大利亚、新西兰拥有33张金融类牌照和资质。基于牌照和优秀的产品服务体验，2020年，公司以新加坡为首站开启国际化战略。截至2021年二季度末，老虎证券全球开户客户数为164.9万，季度内超六成新增入金客户来自海外。此次收购香港证券牌照则代表老虎证券又一个重要里程碑，公司服务区域将得到进一步扩展，为长期发展奠定了更坚实的基础。</p>\n<p>老虎证券成立于2014年，是一家高速成长的全球科技券商，聚焦技术自研，公司旨在通过金融科技提高投资效率，使每个人轻松连接全球资本市场。目前，老虎证券以经纪业务为核心，向全球投资者提供一个账户交易全球主要市场金融产品的一站式投资服务。此外，公司还提供投行、ESOP（股权激励计划）等机构服务以及财富管理、投资者教育等多种增值服务。今年，老虎证券获纳入MSCI中国全股票指数（MSCI China All Shares Index），国际关注度进一步提高。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/2b649bd69bfc05cb75eea3d2165257a2","relate_stocks":{"TIGR":"老虎证券"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1114369979","content_text":"美东时间10月26日盘前，老虎证券（NASDAQ：TIGR）发布公告：公司收购一家香港券商（海悦证券，中央编号：BMU940）已获香港证监会（SFC）批准。该券商持有香港第1、2类牌照，此次收购正式完成后，老虎证券可进入香港市场为当地客户提供证券经纪、期货经纪等服务。\n老虎证券创始人及CEO巫天华表示：“香港一直是全球最活跃的金融市场之一，我们非常期待能进入香港金融市场，结合我们过去七年积累的产品技术、服务经验，为香港当地投资者提供更便捷和优质的全球投资体验，为香港市场高速发展贡献一份力量。”\n此前，老虎证券已在美国、新加坡、澳大利亚、新西兰拥有33张金融类牌照和资质。基于牌照和优秀的产品服务体验，2020年，公司以新加坡为首站开启国际化战略。截至2021年二季度末，老虎证券全球开户客户数为164.9万，季度内超六成新增入金客户来自海外。此次收购香港证券牌照则代表老虎证券又一个重要里程碑，公司服务区域将得到进一步扩展，为长期发展奠定了更坚实的基础。\n老虎证券成立于2014年，是一家高速成长的全球科技券商，聚焦技术自研，公司旨在通过金融科技提高投资效率，使每个人轻松连接全球资本市场。目前，老虎证券以经纪业务为核心，向全球投资者提供一个账户交易全球主要市场金融产品的一站式投资服务。此外，公司还提供投行、ESOP（股权激励计划）等机构服务以及财富管理、投资者教育等多种增值服务。今年，老虎证券获纳入MSCI中国全股票指数（MSCI China All Shares Index），国际关注度进一步提高。","news_type":1},"isVote":1,"tweetType":1,"viewCount":659,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":818607698,"gmtCreate":1630400447114,"gmtModify":1631891021873,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>老虎来了🐯🐯🐯","listText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>老虎来了🐯🐯🐯","text":"$老虎证券(TIGR)$老虎来了🐯🐯🐯","images":[{"img":"https://static.tigerbbs.com/2b3db5dfa6d2f15308b0a95dba4d1967","width":"1242","height":"2001"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/818607698","isVote":1,"tweetType":1,"viewCount":616,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":841746348,"gmtCreate":1635945858637,"gmtModify":1635946855287,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"时间证明一切。世界卫生组织所承认的其中一款疫苗。https://www.who.int/news/item/26-10-2021-who-statement-on-solidarity-trial-vaccines","listText":"时间证明一切。世界卫生组织所承认的其中一款疫苗。https://www.who.int/news/item/26-10-2021-who-statement-on-solidarity-trial-vaccines","text":"时间证明一切。世界卫生组织所承认的其中一款疫苗。https://www.who.int/news/item/26-10-2021-who-statement-on-solidarity-trial-vaccines","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841746348","repostId":"2180628751","repostType":2,"isVote":1,"tweetType":1,"viewCount":774,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":825889408,"gmtCreate":1634217036604,"gmtModify":1634217036658,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"Like please 👍🏻&nbsp;","listText":"Like please 👍🏻&nbsp;","text":"Like please 👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825889408","repostId":"2175518141","repostType":2,"repost":{"id":"2175518141","kind":"highlight","pubTimestamp":1634181120,"share":"https://www.laohu8.com/m/news/2175518141?lang=&edition=full","pubTime":"2021-10-14 11:12","market":"us","language":"en","title":"4 Growth Stocks With 187% to 434% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2175518141","media":"Motley Fool","summary":"Based on analysts' loftiest price targets, these companies could nearly triple or potentially quintuple investors' money over the next year.","content":"<p>For much of the past 18 months, Wall Street and investors have enjoyed an historic stock market rally. Since bottoming out on March 23, 2020, the widely followed <b>S&amp;P 500</b> has doubled in value. For some context, the S&amp;P 500 has average an annualized total return (including dividends paid) of closer to 11% since the beginning of 1980.</p>\n<p>But for some stocks, there's plenty of upside still to come. According to high-water price targets from select analysts and/or Wall Street investment banks, the following four growth stocks offer share-price upside ranging from a low of 187% to a high of 434% over the coming 12 months.</p>\n<h2>Plug Power: Implied upside of 187%</h2>\n<p>The first high-growth stock with the potential to get investors' motors running is hydrogen fuel-cell solutions provider <b>Plug Power</b> (NASDAQ:PLUG). Analyst Amit Dayal of H.C. Wainwright sees Plug Power heading to $78, which is a far cry from its closing price of $27.19, as of this past weekend. Dayal's Street-high price target implies a 187% increase in Plug's shares.</p>\n<p>The excitement surrounding Plug Power has to do with developed countries emphasizing green-energy alternatives to reduce carbon emissions. Plug's hydrogen fuel cells can be used to power consumer and commercial vehicles, and they have industrial applications, as well (e.g., forklifts). Further, there's an opportunity for the company to benefit at multiple levels of this green-energy shift, such as in building hydrogen refilling stations.</p>\n<p>The buzz surrounding this company hit a crescendo in January, shortly after Plug landed two major partnerships. First, SK Group took a 10% equity stake in the company and agreed to form a joint venture to bring fuel-cell technology to South Korea and other Asian countries. A few days later, Plug and French automaker <b>Renault</b> struck an agreement to form a joint venture to go after Europe's light commercial-vehicle market.</p>\n<p>There's absolutely no question that Plug Power has top-notch joint-venture partners and an incredible opportunity at its doorstep. The big question is: Can it grow into its current $16 billion market cap with profitability still years away? To that end, I'm not so certain.</p>\n<h2>Columbia Care: Implied upside of 228%</h2>\n<p>Marijuana stocks are another source of supercharged growth potential. In particular, U.S. multistate operator (MSO) <b>Columbia Care</b> (OTC:CCHWF) offers jaw-dropping upside. With the highest price target on Wall Street calling for $12 a share, and Columbia Care ending the previous week at $3.66, the upside potential here totals 228% over the coming year.</p>\n<p>Like a number of smartly run MSOs, Columbia Care has predominantly targeted limited-license cannabis markets. These are markets where regulators purposely limit how many dispensaries can open, as well as how many licenses a single business can hold. By planting its flag in limited-license markets like Ohio, Virginia, and Pennsylvania, Columbia Care is ensuring that it'll have a fair shot to build up its brands and garner a loyal following in potential billion-dollar markets without being overrun by other MSOs that have deeper pockets.</p>\n<p>The other factor that really stands out with Columbia Care is its penchant for inorganic growth. This is a company that's been pulling the trigger on multiple acquisitions each year to expand its reach. As of last week, it had 75 operating dispensaries in legalized states.</p>\n<p>For the moment, the <a href=\"https://laohu8.com/S/AONE.U\">one</a>-time costs associated with acquisitions appears to be holding down Columbia Care's bottom line, as well as its valuation. But if the company's management team can effectively build up its brand in a number of key markets, this lofty price target may not be out of reach.</p>\n<h2>Exelixis: Implied upside of 201%</h2>\n<p>Biotech stocks can be like the roulette wheel of Wall Street. While the odds of a company developing a breakthrough drug aren't great, the payoff, if successful, can be huge.</p>\n<p>In the case of <b>Exelixis</b> (NASDAQ:EXEL), the payoff has been substantial. But according to analyst Michael King of H.C. Wainwright, this company has the potential to hit $65 a share. This would effectively triple its valuation, based on where it closed this past week.</p>\n<p>The key to Exelixis' long-term success rests with cancer drug Cabometyx, which is approved to treat first- and second-line renal cell carcinoma and advanced hepatocellular carcinoma. By no later than next year, it should be generating north of $1 billion in recurring annual sales.</p>\n<p>What's so intriguing about Exelixis' lead drug is that it's being studied in approximately six dozen clinical trials as a combination treatment or monotherapy. Though not all of these studies will be successful, it nevertheless offers a solid opportunity for Cabometyx's label to expand over time.</p>\n<p>Exelixis is also sitting on a mountain of cash and investments -- it's expected to end the year with between $1.7 billion and $1.8 billion. This capital is helping to fuel its internal research engine and could be used to acquire other therapies or businesses. While I don't believe Exelixis will come close to $65 a share in the near term, I do foresee healthy upside in its future.</p>\n<h2>Inovio Pharmaceuticals: Implied upside of 434%</h2>\n<p>But the crème de la crème of upside opportunity, at least on this list, is clinical-stage biotech stock <b>Inovio Pharmaceuticals</b> (NASDAQ:INO). According to analyst Hartaj Singh of Oppenheimer, Inovio is forecast to hit $35 a share. Based on its $6.55 closing price last week, this implies up to 434% upside in Inovio's shares.</p>\n<p>Most of Singh's bullishness is centered around Inovio's development of a coronavirus disease 2019 (COVID-19) vaccine. With billions of people worldwide still needing to be inoculated, there's room for additional vaccine players.</p>\n<p>On the other hand, Inovio's development of its COVID-19 vaccine, INO-4800, has been just as dubious as its long-term drug-development track record. Last year, it looked as if Inovio had a real shot to be one of the first developers to hit the market with a COVID-19 vaccine. Unfortunately, Inovio's plans were derailed by partial clinical holds in the United States. To boot, the U.S. eventually pulled phase 3 trial funding, which has forced Inovio to conduct its large-scale phase 3 study in Mexico and other countries around the globe.</p>\n<p>Perhaps the bigger worry here is that, despite a robust clinical pipeline, Inovio has yet to bring a drug to pharmacy shelves more than 40 years after its founding. Inovio has been lucky enough to raise capital to keep its research going, but it's never been able to deliver on the hype surrounding the company. Suffice it to say, I don't foresee a $35 price target coming to fruition anytime soon, if ever.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Growth Stocks With 187% to 434% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Growth Stocks With 187% to 434% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-14 11:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/13/4-growth-stocks-with-187-to-434-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For much of the past 18 months, Wall Street and investors have enjoyed an historic stock market rally. Since bottoming out on March 23, 2020, the widely followed S&P 500 has doubled in value. For some...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/13/4-growth-stocks-with-187-to-434-upside-wall-street/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLUG":"普拉格能源","EXEL":"伊克力西斯","INO":"伊诺维奥制药"},"source_url":"https://www.fool.com/investing/2021/10/13/4-growth-stocks-with-187-to-434-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175518141","content_text":"For much of the past 18 months, Wall Street and investors have enjoyed an historic stock market rally. Since bottoming out on March 23, 2020, the widely followed S&P 500 has doubled in value. For some context, the S&P 500 has average an annualized total return (including dividends paid) of closer to 11% since the beginning of 1980.\nBut for some stocks, there's plenty of upside still to come. According to high-water price targets from select analysts and/or Wall Street investment banks, the following four growth stocks offer share-price upside ranging from a low of 187% to a high of 434% over the coming 12 months.\nPlug Power: Implied upside of 187%\nThe first high-growth stock with the potential to get investors' motors running is hydrogen fuel-cell solutions provider Plug Power (NASDAQ:PLUG). Analyst Amit Dayal of H.C. Wainwright sees Plug Power heading to $78, which is a far cry from its closing price of $27.19, as of this past weekend. Dayal's Street-high price target implies a 187% increase in Plug's shares.\nThe excitement surrounding Plug Power has to do with developed countries emphasizing green-energy alternatives to reduce carbon emissions. Plug's hydrogen fuel cells can be used to power consumer and commercial vehicles, and they have industrial applications, as well (e.g., forklifts). Further, there's an opportunity for the company to benefit at multiple levels of this green-energy shift, such as in building hydrogen refilling stations.\nThe buzz surrounding this company hit a crescendo in January, shortly after Plug landed two major partnerships. First, SK Group took a 10% equity stake in the company and agreed to form a joint venture to bring fuel-cell technology to South Korea and other Asian countries. A few days later, Plug and French automaker Renault struck an agreement to form a joint venture to go after Europe's light commercial-vehicle market.\nThere's absolutely no question that Plug Power has top-notch joint-venture partners and an incredible opportunity at its doorstep. The big question is: Can it grow into its current $16 billion market cap with profitability still years away? To that end, I'm not so certain.\nColumbia Care: Implied upside of 228%\nMarijuana stocks are another source of supercharged growth potential. In particular, U.S. multistate operator (MSO) Columbia Care (OTC:CCHWF) offers jaw-dropping upside. With the highest price target on Wall Street calling for $12 a share, and Columbia Care ending the previous week at $3.66, the upside potential here totals 228% over the coming year.\nLike a number of smartly run MSOs, Columbia Care has predominantly targeted limited-license cannabis markets. These are markets where regulators purposely limit how many dispensaries can open, as well as how many licenses a single business can hold. By planting its flag in limited-license markets like Ohio, Virginia, and Pennsylvania, Columbia Care is ensuring that it'll have a fair shot to build up its brands and garner a loyal following in potential billion-dollar markets without being overrun by other MSOs that have deeper pockets.\nThe other factor that really stands out with Columbia Care is its penchant for inorganic growth. This is a company that's been pulling the trigger on multiple acquisitions each year to expand its reach. As of last week, it had 75 operating dispensaries in legalized states.\nFor the moment, the one-time costs associated with acquisitions appears to be holding down Columbia Care's bottom line, as well as its valuation. But if the company's management team can effectively build up its brand in a number of key markets, this lofty price target may not be out of reach.\nExelixis: Implied upside of 201%\nBiotech stocks can be like the roulette wheel of Wall Street. While the odds of a company developing a breakthrough drug aren't great, the payoff, if successful, can be huge.\nIn the case of Exelixis (NASDAQ:EXEL), the payoff has been substantial. But according to analyst Michael King of H.C. Wainwright, this company has the potential to hit $65 a share. This would effectively triple its valuation, based on where it closed this past week.\nThe key to Exelixis' long-term success rests with cancer drug Cabometyx, which is approved to treat first- and second-line renal cell carcinoma and advanced hepatocellular carcinoma. By no later than next year, it should be generating north of $1 billion in recurring annual sales.\nWhat's so intriguing about Exelixis' lead drug is that it's being studied in approximately six dozen clinical trials as a combination treatment or monotherapy. Though not all of these studies will be successful, it nevertheless offers a solid opportunity for Cabometyx's label to expand over time.\nExelixis is also sitting on a mountain of cash and investments -- it's expected to end the year with between $1.7 billion and $1.8 billion. This capital is helping to fuel its internal research engine and could be used to acquire other therapies or businesses. While I don't believe Exelixis will come close to $65 a share in the near term, I do foresee healthy upside in its future.\nInovio Pharmaceuticals: Implied upside of 434%\nBut the crème de la crème of upside opportunity, at least on this list, is clinical-stage biotech stock Inovio Pharmaceuticals (NASDAQ:INO). According to analyst Hartaj Singh of Oppenheimer, Inovio is forecast to hit $35 a share. Based on its $6.55 closing price last week, this implies up to 434% upside in Inovio's shares.\nMost of Singh's bullishness is centered around Inovio's development of a coronavirus disease 2019 (COVID-19) vaccine. With billions of people worldwide still needing to be inoculated, there's room for additional vaccine players.\nOn the other hand, Inovio's development of its COVID-19 vaccine, INO-4800, has been just as dubious as its long-term drug-development track record. Last year, it looked as if Inovio had a real shot to be one of the first developers to hit the market with a COVID-19 vaccine. Unfortunately, Inovio's plans were derailed by partial clinical holds in the United States. To boot, the U.S. eventually pulled phase 3 trial funding, which has forced Inovio to conduct its large-scale phase 3 study in Mexico and other countries around the globe.\nPerhaps the bigger worry here is that, despite a robust clinical pipeline, Inovio has yet to bring a drug to pharmacy shelves more than 40 years after its founding. Inovio has been lucky enough to raise capital to keep its research going, but it's never been able to deliver on the hype surrounding the company. Suffice it to say, I don't foresee a $35 price target coming to fruition anytime soon, if ever.","news_type":1},"isVote":1,"tweetType":1,"viewCount":686,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":826034606,"gmtCreate":1633957257586,"gmtModify":1633957257586,"author":{"id":"3568282478603632","authorId":"3568282478603632","name":"小宝8816","avatar":"https://static.tigerbbs.com/6893c5a0dd86f71437fc01bfd123bc73","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3568282478603632","authorIdStr":"3568282478603632"},"themes":[],"htmlText":"第三期DNA疫苗。哥伦比亚。接下来会有更多国家参与!","listText":"第三期DNA疫苗。哥伦比亚。接下来会有更多国家参与!","text":"第三期DNA疫苗。哥伦比亚。接下来会有更多国家参与!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/826034606","repostId":"2174902634","repostType":2,"isVote":1,"tweetType":1,"viewCount":797,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}